Core Insights - BrightGene Pharmaceutical Co., Ltd. presented promising Phase II clinical trial data for its dual-target agonist BGM0504 at the 85th American Diabetes Association (ADA) Scientific Sessions, indicating potential advantages over Semaglutide in treating type 2 diabetes and obesity [1][4] - The company also shared preclinical results for a new Amylin, BGM1812, which shows enhanced receptor activation and potential for effective weight management [1][5] Group 1: BGM0504 Clinical Data - BGM0504 demonstrated significant reductions in HbA1c, fasting blood glucose, postprandial blood glucose, weight, and blood pressure in adult patients with type 2 diabetes during Phase II trials [3][4] - The majority of adverse events were mild to moderate and resolved without intervention, with no observed cases of hypoglycemia or unexpected adverse events, indicating a favorable risk-benefit profile [3][4] - The drug is currently undergoing Phase III clinical trials in China for weight management and type 2 diabetes, with over 1,000 patients treated, showing excellent efficacy and safety [4] Group 2: BGM1812 Development - BGM1812 is a novel Amylin designed using AI/ML optimization, characterized by strong and prolonged effects, with potential for development into a weekly oral formulation [5] - The company aims to leverage its expertise in peptide development to accelerate innovative therapies for unmet clinical needs in metabolic diseases [4]

China (PRC) | Healthcare Equity Research China Force in ADA 2025 All eyes on ADA'25 with key presentations during this weekend, e.g.LLY's Orfo and Bima. China biotechs will also have a presence with notable data to watch: 1) Ascletis's ASC30 (orfo-structure oral GLP-1) in Ph1, 2) Laekna's LAE102 (muscle preserving) in Ph1 and 3) Innovent's Mazdutide (GLP-1/ GCG) Ph3 data in T2D. We don't anticipate major surprises from China in ADA'25 though given oral GLP-1 and amylin candidates in early stages and no key ...

根据联合声明发表的最新关税政策，中美之间最高 145%的关税在 5 月 14 日之前降至 30%（由 10%的对等关税和 20%的芬太尼关税组成）， 7 月 9 日视情况恢复至 54%或再协商，91%的报复性关税完全取消，出口 的不确定性影响进一步降低。中美发布联合声明是一个较为重要的举措， 关税商谈的进展顺利程度和发布效率远超市场预期。美国在此次对我方 做出了较大让步后，后续的贸易框架协定有望在年内谈成。最终达成的完 整版协议可能仍然将通过以打促谈的模式，也有可能再迎来具体行业的 关税反复，需要观察未来针对部分产品名录的惩罚性关税和 232 调查最 终的结果。 本次谈判超预期的主要原因在于美国国内日渐增长的政 治压力和经济压力。考虑到明年 11 月的中期选举投票，今年对其他主要 贸易国家的框架协议将作为特朗普的"政绩"，7 月的缓和期到期后将进 入框架协议的谈判高峰，时间较为紧迫。另外，关税冲突对经济数据的不 确定性依旧高企，3 月美国商品和服务贸易逆差环比增长 14%，消费品进 口创历史新高，美国消费品库存压力大，"抢进口"效应愈发明显，美国 对于关税下降的诉求相对中国来说更为紧迫。 风险提示：美国关税政 ...

证券研究报告·公司点评报告·化学制药 博瑞医药（688166） 定向增发点评与公司近况更新：募资 5 亿， 实控人全额认购，管线进展顺利，催化丰富 【勘误版】 增持（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 1,180 | 1,283 | 1,295 | 1,490 | 1,762 | | 同比（%） | 15.94 | 8.74 | 0.95 | 15.11 | 18.21 | | 归母净利润（百万元） | 202.47 | 189.17 | 261.90 | 302.94 | 433.39 | | 同比（%） | (15.51) | (6.57) | 38.45 | 15.67 | 43.06 | | EPS-最新摊薄（元/股） | 0.48 | 0.45 | 0.62 | 0.72 | 1.03 | | P/E（现价&最新摊薄） | 107.15 | 114.68 | 82.83 | 71.61 | 50. ...

证券研究报告·公司点评报告·化学制药 博瑞医药（688166） 定向增发点评与公司近况更新：募资 5 亿， 实控人全额认购，管线进展顺利，催化丰富 【勘误版】 增持（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 1,180 | 1,283 | 1,295 | 1,490 | 1,762 | | 同比（%） | 15.94 | 8.74 | 0.95 | 15.11 | 18.21 | | 归母净利润（百万元） | 202.47 | 189.17 | 261.90 | 302.94 | 433.39 | | 同比（%） | (15.51) | (6.57) | 38.45 | 15.67 | 43.06 | | EPS-最新摊薄（元/股） | 0.48 | 0.45 | 0.62 | 0.72 | 1.03 | | P/E（现价&最新摊薄） | 107.15 | 114.68 | 82.83 | 71.61 | 50. ...

证券研究报告 东吴证券晨会纪要 东吴证券晨会纪要 2025-05-12 [Table_Tag] 宏观策略 [Table_MacroStrategy] 宏观深度报告 20250508：基于 38 个国家的比较：为何我国消费率偏低 我国居民可支配收入比重高于国际平均、消费倾向低于国际平均，是否说 明我国居民部门"有钱不愿花"？并非如此，由于个税和财产税主要影响 少数中高收入者，因此剔除中高收入者后，对大多数居民而言，我国跟其 他国家居民收入比重的国际比较结果可能是 61.3%VS66.3%，而非 60%VS58.2%。即中高收入者存在"有钱不花"、消费倾向低的现象，但 大多数居民仍然是有消费意愿但缺少消费能力，因此 2025 年 4 月政治局 会议指出"要提高中低收入群体收入"是很有必要的。 10、居民所得税 和财产税的税负轻并不一定有利于消费。我国居民税负和社保净收入"双 低"的格局，意味着二次分配环节没有充分发挥调节收入差距的作用，不 利于促进消费。我们发现，如果将居民个税和财产税的税负提高到跟 38 国平均水平一致，提高税负的同时提高转移支付水平，将增加的这部分税 收以转移支付的形式全部给予中低收入者，可以 ...

证券研究报告·公司点评报告·化学制药 博瑞医药（688166） 定向增发点评与公司近况更新：募资 5 亿， 实控人全额认购，管线进展顺利，催化丰富 增持（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 1,180 | 1,283 | 1,295 | 1,490 | 1,762 | | 同比（%） | 15.94 | 8.74 | 0.95 | 15.11 | 18.21 | | 归母净利润（百万元） | 202.47 | 189.17 | 261.90 | 302.94 | 433.39 | | 同比（%） | (15.51) | (6.57) | 38.45 | 15.67 | 43.06 | | EPS-最新摊薄（元/股） | 0.48 | 0.45 | 0.62 | 0.72 | 1.03 | | P/E（现价&最新摊薄） | 107.15 | 114.68 | 82.83 | 71.61 | 50.06 | [ ...

Investment Rating - The report maintains a "Buy" rating for the company [2]. Core Views - The company focuses on the research and development of metabolic drugs, with new pipeline additions including oral BGM0504 and Amylin analog BGM1812. The current strategy emphasizes developing innovative drugs with global intellectual property rights in the metabolic disease field [5][17]. - The company reported a revenue of 1.283 billion yuan in 2024, an increase of 8.74% year-on-year, while the net profit attributable to the parent company was 189 million yuan, a decrease of 6.57% [5]. - The company expects revenues of 1.444 billion yuan in 2025, with a year-on-year growth of 12.6%, and net profits of 253 million yuan, reflecting a growth of 33.7% [5]. Summary by Sections Market Performance - The company's stock price has shown a relative increase compared to the CSI 300 index, with absolute growth rates of 11.71% over 1 month, 17.10% over 2 months, and 48.00% over 3 months [4]. Financial Data - In 2024, the company achieved a gross margin of 58.62%, an increase of 2.5 percentage points year-on-year. The R&D expenses for 2024 were 297 million yuan, a year-on-year increase of 19.65%, reflecting the company's commitment to a "R&D-driven" strategy [5][6]. Product Pipeline - The company is advancing its innovative drug development, with BGM0504 injection for type 2 diabetes and weight loss currently in phase III clinical trials in China, and the oral formulation BGM0504 is in preclinical stages [5][9][17]. - BGM1812, an Amylin analog, is also in the pipeline, targeting metabolic diseases and expected to complement GLP-1 drugs for enhanced weight loss effects [17][18]. Revenue Forecast - The company forecasts revenues of 1.641 billion yuan in 2026 and 1.889 billion yuan in 2027, with corresponding net profits of 297 million yuan and 363 million yuan, indicating a strong growth trajectory [6].

Investment Rating - The report maintains a "Buy" rating for the company [2] Core Views - The company focuses on the research and development of metabolic drugs, with new pipeline additions including oral BGM0504 and Amylin analog BGM1812 [5] - The company reported a revenue of 1.283 billion yuan in 2024, an increase of 8.74%, while the net profit attributable to the parent company was 189 million yuan, a decrease of 6.57% [5] - The company expects revenue growth of 12.6%, 13.7%, and 15.1% for the years 2025, 2026, and 2027, respectively, with net profit growth of 33.7%, 17.6%, and 22.0% during the same period [5] Financial Performance - In 2024, the company achieved a gross margin of 58.62%, an increase of 2.5 percentage points year-on-year [5] - The R&D expenses for 2024 were 297 million yuan, a year-on-year increase of 19.65%, reflecting the company's commitment to a "R&D-driven" strategy [5] - The company’s total assets were reported at 5.285 billion yuan, with a total market value of approximately 18.576 billion yuan [6] Market Comparison - The company’s stock performance showed an absolute increase of 11.71% over one month, 17.10% over two months, and 48.00% over three months [4] - Compared to the CSI 300 index, the company outperformed with a relative increase of 15.09%, 21.46%, and 49.19% over the same periods [4] Research and Development Focus - The company is developing BGM0504, an oral formulation that aims to overcome the challenges of oral peptide delivery, which has high technical barriers globally [9][10] - BGM1812, an Amylin analog, is positioned to complement GLP-1 drugs in weight management and blood sugar control [17] - The company is advancing its clinical trials for BGM0504, with both Type 2 diabetes and weight loss indications progressing as planned [5]